201 related articles for article (PubMed ID: 18402650)
21. Prokinetics and fundic relaxants in upper functional GI disorders.
Tack J
Curr Opin Pharmacol; 2008 Dec; 8(6):690-6. PubMed ID: 18940266
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
Dobrek Ł; Thor PJ
Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
[TBL] [Abstract][Full Text] [Related]
23. Functional gastrointestinal disorders as a public health problem.
Talley NJ
Neurogastroenterol Motil; 2008 May; 20 Suppl 1():121-9. PubMed ID: 18402649
[TBL] [Abstract][Full Text] [Related]
24. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
Alavijeh MS; Palmer AM
IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
[TBL] [Abstract][Full Text] [Related]
25. [Gastrointestinal motility disorders and drugs: cholinergic, anticholinergic, adrenergic, antiadrenergic and prokinetic drugs (part I)].
Jovanović-Mićić D; Janković S; Beleslin DB
Srp Arh Celok Lek; 1994; 122(1-2):50-4. PubMed ID: 17972806
[TBL] [Abstract][Full Text] [Related]
26. Central nervous system involvement in functional gastrointestinal disorders.
Van Oudenhove L; Demyttenaere K; Tack J; Aziz Q
Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):663-80. PubMed ID: 15324706
[TBL] [Abstract][Full Text] [Related]
27. The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire.
Nakajima S
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S186-92. PubMed ID: 19120896
[TBL] [Abstract][Full Text] [Related]
28. Use of natural products in gastrointestinal therapies.
Brierley SM; Kelber O
Curr Opin Pharmacol; 2011 Dec; 11(6):604-11. PubMed ID: 21996284
[TBL] [Abstract][Full Text] [Related]
29. Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders.
Martinucci I; Blandizzi C; de Bortoli N; Bellini M; Antonioli L; Tuccori M; Fornai M; Marchi S; Colucci R
Pharmacogenomics; 2015; 16(5):523-39. PubMed ID: 25916523
[TBL] [Abstract][Full Text] [Related]
30. Ophthalmic drug discovery.
Clark AF; Yorio T
Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220
[TBL] [Abstract][Full Text] [Related]
31. Failed therapy and directions for the future in dyspepsia.
Holtmann G; Gapasin J
Dig Dis; 2008; 26(3):218-24. PubMed ID: 18463439
[TBL] [Abstract][Full Text] [Related]
32. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
Stebbing J; Wood C; Atkins M; Bukowski R; Litwin S; Bower M; Parsa A; Levitsky H
Cancer; 2008 Mar; 112(5):955-61. PubMed ID: 18286505
[TBL] [Abstract][Full Text] [Related]
33. Development of medications for alcohol use disorders: recent advances and ongoing challenges.
Litten RZ; Fertig J; Mattson M; Egli M
Expert Opin Emerg Drugs; 2005 May; 10(2):323-43. PubMed ID: 15934870
[TBL] [Abstract][Full Text] [Related]
34. Multicenter study of gastroenterologists' ability to identify anxiety and depression in a new patient encounter and its impact on diagnosis.
Keefer L; Sayuk G; Bratten J; Rahimi R; Jones MP
J Clin Gastroenterol; 2008 Jul; 42(6):667-71. PubMed ID: 18496395
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
Camilleri M; Talley NJ
Neurogastroenterol Motil; 2004 Apr; 16(2):135-42. PubMed ID: 15086867
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
Boeckxstaens GE
Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
[No Abstract] [Full Text] [Related]
37. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
38. In silico prediction of clinical efficacy.
Michelson S; Sehgal A; Friedrich C
Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
[TBL] [Abstract][Full Text] [Related]
39. Genomics in drug discovery: the best things come to those who wait.
Bansal AT; Barnes MR
Curr Opin Drug Discov Devel; 2008 May; 11(3):303-11. PubMed ID: 18428083
[TBL] [Abstract][Full Text] [Related]
40. Molecular, functional, and pharmacological targets for the development of gut promotility drugs.
Sarna SK
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G545-55. PubMed ID: 16565417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
